US Pharma MarketingFDA AdCom shuns Capricor’s DMD cell therapy amid data dispute
FDA AdCom shuns Capricor’s DMD cell therapy amid data dispute is a pharma and life sciences industry update from Pharmaceutical Technology. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Capricor is adamant its Phase III study showed effectiveness, though panel members called data “fragile”.
Source: Pharmaceutical Technology